{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T21:27:29Z","timestamp":1760909249803},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2020,9,14]],"date-time":"2020-09-14T00:00:00Z","timestamp":1600041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,9,14]],"date-time":"2020-09-14T00:00:00Z","timestamp":1600041600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["HNO"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s00106-020-00926-w","type":"journal-article","created":{"date-parts":[[2020,9,14]],"date-time":"2020-09-14T22:02:42Z","timestamp":1600120962000},"page":"927-934","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Das Tumormikromilieu bei Speicheldr\u00fcsenkarzinomen \u2013 m\u00f6gliche Konsequenzen f\u00fcr neue Therapiekonzepte"],"prefix":"10.1007","volume":"68","author":[{"given":"M. F.","family":"Meyer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Arolt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B. A.","family":"Kansy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Doescher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Quaas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Beutner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Lang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. P.","family":"Klu\u00dfmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,9,14]]},"reference":[{"key":"926_CR1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-020-02551-6","author":"C Arolt","year":"2020","unstructured":"Arolt\u00a0C, Meyer\u00a0M, Ruesseler\u00a0V et al (2020) Lymphocyte activation gene 3 (LAG3) protein expression on tumor-infiltrating lymphocytes in aggressive and TP53-mutated salivary gland carcinomas. Cancer Immunol Immunother. https:\/\/doi.org\/10.1007\/s00262-020-02551-6","journal-title":"Cancer Immunol Immunother"},{"key":"926_CR2","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1055\/s-0034-1382024","volume":"93","author":"K B\u00fcchsensch\u00fctz","year":"2014","unstructured":"B\u00fcchsensch\u00fctz\u00a0K, Veit\u00a0JA, Schuler\u00a0PJ et\u00a0al (2014) Molecular approaches to systemic therapy of adenoid cystic carcinoma of the head and neck area. Laryngorhinootologie 93:657\u2013664","journal-title":"Laryngorhinootologie"},{"key":"926_CR3","doi-asserted-by":"publisher","first-page":"6545","DOI":"10.4049\/jimmunol.0903879","volume":"184","author":"C Camisaschi","year":"2010","unstructured":"Camisaschi\u00a0C, Casati\u00a0C, Rini\u00a0F et al (2010) LAG\u20113 expression defines a\u00a0subset of CD4+CD25highFoxp3+ regulatory T cells that are expanded at tumor sites. J\u00a0Immunol 184:6545\u20136551","journal-title":"J Immunol"},{"key":"926_CR4","doi-asserted-by":"publisher","first-page":"2983","DOI":"10.2147\/OTT.S134589","volume":"10","author":"H Chang","year":"2017","unstructured":"Chang\u00a0H, Kim\u00a0JS, Choi\u00a0YJ et al (2017) Overexpression of PD-L2 is associated with shorter relapse-free survival in patients with malignant salivary gland tumors. OncoTargets Ther 10:2983\u20132992","journal-title":"OncoTargets Ther"},{"key":"926_CR5","doi-asserted-by":"publisher","DOI":"10.1097\/COC.0000000000000429","author":"RB Cohen","year":"2018","unstructured":"Cohen\u00a0RB, Delord\u00a0JP, Doi\u00a0T et al (2018) Pembrolizumab for the treatment of advanced salivary gland carcinoma: findings of the phase 1b\u00a0KEYNOTE-028\u00a0study. Am J Clin Oncol. https:\/\/doi.org\/10.1097\/COC.0000000000000429","journal-title":"Am J Clin Oncol"},{"key":"926_CR6","doi-asserted-by":"publisher","first-page":"e1239005","DOI":"10.1080\/2162402X.2016.1239005","volume":"5","author":"WW Deng","year":"2016","unstructured":"Deng\u00a0WW, Mao\u00a0L, Yu\u00a0GT et al (2016) LAG\u20113 confers poor prognosis and its blockade reshapes antitumor response in head and neck squamous cell carcinoma. OncoImmunology 5:e1239005","journal-title":"OncoImmunology"},{"key":"926_CR7","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1007\/s00106-019-00760-9","volume":"67","author":"J Doescher","year":"2019","unstructured":"Doescher\u00a0J, Schuler\u00a0PJ, Greve\u00a0J et al (2019) Salivary gland malignancies-highlights of the 2019 ASCO Annual Meeting. HNO 67:931\u2013934","journal-title":"HNO"},{"key":"926_CR8","doi-asserted-by":"publisher","first-page":"6083","DOI":"10.1200\/JCO.2019.37.15_suppl.6083","volume":"37","author":"J Fayette","year":"2019","unstructured":"Fayette\u00a0J, Even\u00a0C, Digue\u00a0L et\u00a0al (2019) NISCAHN: A phase II,multicenter nonrandomized trial aiming at evaluating nivolumab (N) in two cohorts of patients (pts) with recurrent\/metastatic (R\/M) salivary gland carcinoma of the head and neck (SGCHN), on behalf of the Unicancer Head & Neck Group. J\u00a0Clin Oncol 37:6083","journal-title":"J Clin Oncol"},{"key":"926_CR9","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1056\/NEJMc1616177","volume":"376","author":"R Ferris","year":"2017","unstructured":"Ferris\u00a0R, Gillison\u00a0ML (2017) Nivolumab for squamous-cell cancer of head and neck. N\u00a0Engl J Med 376:596","journal-title":"N Engl J Med"},{"key":"926_CR10","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.cell.2010.01.025","volume":"140","author":"SI Grivennikov","year":"2010","unstructured":"Grivennikov\u00a0SI, Greten\u00a0FR, Karin\u00a0M (2010) Immunity, inflammation, and cancer. Cell 140:883\u2013899","journal-title":"Cell"},{"key":"926_CR11","doi-asserted-by":"publisher","first-page":"18224","DOI":"10.18632\/oncotarget.4015","volume":"6","author":"I Gr\u00fcnewald","year":"2015","unstructured":"Gr\u00fcnewald\u00a0I, Vollbrecht\u00a0C, Meinrath\u00a0J et\u00a0al (2015) Targeted next generation sequencing of parotid gland cancer uncovers genetic heterogeneity. Oncotarget 6:18224\u201318237","journal-title":"Oncotarget"},{"key":"926_CR12","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1007\/s00066-017-1196-8","volume":"193","author":"M Haderlein","year":"2017","unstructured":"Haderlein\u00a0M, Scherl\u00a0C, Semrau\u00a0S et\u00a0al (2017) Impact of postoperative radiotherapy and HER2\/new overexpression in salivary duct carcinoma. Strahlenther Onkol 193:961\u2013970","journal-title":"Strahlenther Onkol"},{"key":"926_CR13","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1038\/s41467-018-08069-x","volume":"10","author":"F Haller","year":"2019","unstructured":"Haller\u00a0F, Bieg\u00a0M, Will\u00a0R et\u00a0al (2019) Enhancer hijacking activates oncogenic transcription factor NR4A3 in acinic cell carcinomas of the salivary glands. Nat Commun 10:368","journal-title":"Nat Commun"},{"key":"926_CR14","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s12885-018-4069-3","volume":"18","author":"K Harada","year":"2018","unstructured":"Harada\u00a0K, Ferdous\u00a0T, Ueyama\u00a0K (2018) PD-L1 expression in malignant salivary gland tumors. BMC Cancer 18:156","journal-title":"BMC Cancer"},{"key":"926_CR15","doi-asserted-by":"publisher","first-page":"2718","DOI":"10.1002\/eji.1830250949","volume":"25","author":"B Huard","year":"1995","unstructured":"Huard\u00a0B, Prigent\u00a0P, Tournier\u00a0M et al (1995) CD4\/major histocompatibility complex class II interaction analyzed with CD4- and lymphocyte activation gene\u20113 (LAG-3)-Ig fusion proteins. Eur J Immunol 25:2718\u20132721","journal-title":"Eur J Immunol"},{"key":"926_CR16","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/his.13845","volume":"75","author":"YP Hung","year":"2019","unstructured":"Hung\u00a0YP, Jo\u00a0VY, Hornick\u00a0JL (2019) Immunhistochemistry with pan-TRK antibody distinguishes secretory carcinoma of the salivary galnd from acinic cell carcinoma. Histopathology 75:54\u201362","journal-title":"Histopathology"},{"key":"926_CR17","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1007\/s00405-019-05363-2","volume":"276","author":"SS Jeske","year":"2019","unstructured":"Jeske\u00a0SS, Weissinger\u00a0SE, Veit\u00a0JA et\u00a0al (2019) Treatment induced changes of lymphocyte subsets in patients with adenoid cystic carcinoma of the head and neck. Eur Arch Otorhinolaryngol 276:1465\u20131473","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"926_CR18","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1007\/s00106-005-1294-2","volume":"53","author":"S Lang","year":"2005","unstructured":"Lang\u00a0S, Rotter\u00a0N, Lorenzen\u00a0A et\u00a0al (2005) Salivary gland carcinomas Part II. Diagnosis and therapy. HNO 53:905\u2013911","journal-title":"HNO"},{"key":"926_CR19","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-3758","author":"M Linxweiler","year":"2020","unstructured":"Linxweiler\u00a0M, Kuo\u00a0F, Katabi\u00a0N et\u00a0al (2020) The immune microenvironment and neoantigen landscape of aggressive salivary gland carcinomas differ by subtype. Clin Cancer Res. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-3758","journal-title":"Clin Cancer Res"},{"key":"926_CR20","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.oraloncology.2018.11.028","volume":"88","author":"C Mosconi","year":"2019","unstructured":"Mosconi\u00a0C, de Arruda\u00a0JAA, de Farias\u00a0ACR et\u00a0al (2019) Immune microenvironment and evasion mechanisms in adenoid cystic carcinomas of salivary glands. Oral Oncol 88:95\u2013101","journal-title":"Oral Oncol"},{"key":"926_CR21","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.tranon.2019.11.008","volume":"13","author":"F Perri","year":"2020","unstructured":"Perri\u00a0F, Ionna\u00a0F, Longo\u00a0F et\u00a0al (2020) Immune response against head and neck cancer: biological mechanisms and implication on therapy. Transl Oncol 13:262\u2013274","journal-title":"Transl Oncol"},{"key":"926_CR22","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1002\/ijc.31808","volume":"144","author":"E Pylaeva","year":"2019","unstructured":"Pylaeva\u00a0E, Harati\u00a0MD, Spyra\u00a0I et al (2019) NAMPT signaling is critical for the proangiogenic activity of tumor-associated neutrophils. Int J Cancer 144:136\u2013149","journal-title":"Int J Cancer"},{"key":"926_CR23","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.oraloncology.2017.09.008","volume":"74","author":"NC Schmitt","year":"2017","unstructured":"Schmitt\u00a0NC, Kang\u00a0H, Sharma\u00a0A (2017) Salivary duct carcinoma: An aggressive salivary gland malignancy with opportunities for targeted therapy. Oral Oncol 74:40\u201348","journal-title":"Oral Oncol"},{"key":"926_CR24","doi-asserted-by":"publisher","first-page":"e11","DOI":"10.1097\/PAS.0000000000000980","volume":"42","author":"A Sk\u00e1lov\u00e1","year":"2018","unstructured":"Sk\u00e1lov\u00e1\u00a0A, Stenman\u00a0G, Simpson\u00a0RHW et\u00a0al (2018) The role of molecular testing in the differential diagnosis of salivary gland carcinomas. Am J Surg Pathol 42:e11\u201327","journal-title":"Am J Surg Pathol"},{"key":"926_CR25","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1158\/2326-6066.CIR-16-0031","volume":"4","author":"V Sridharan","year":"2016","unstructured":"Sridharan\u00a0V, Gjini\u00a0E, Liao\u00a0X et al (2016) Immune profiling of adenoid cystic carcinoma: PD-L2 expression and associations with tumor-infiltrating lymphocytes. Cancer Immunol Res 4:679\u2013687","journal-title":"Cancer Immunol Res"},{"key":"926_CR26","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1200\/JCO.18.00545","volume":"37","author":"H Takahashi","year":"2019","unstructured":"Takahashi\u00a0H, Tada\u00a0Y, Saotome\u00a0T et al (2019) Phase II trial of trastuzumab and docetaxel in patients with human epidermal growth factor receptor 2\u2011positive salivary duct carcinoma. J\u00a0Clin Oncol 37:125\u2013134","journal-title":"J Clin Oncol"},{"key":"926_CR27","doi-asserted-by":"publisher","first-page":"12724","DOI":"10.1038\/s41598-019-49215-9","volume":"9","author":"D Vital","year":"2019","unstructured":"Vital\u00a0D, Ikenberg\u00a0K, Moch\u00a0H et al (2019) The expression of PD-L1 in salivary gland carcinomas. Sci Rep 9:12724","journal-title":"Sci Rep"},{"key":"926_CR28","doi-asserted-by":"publisher","first-page":"3946","DOI":"10.18632\/oncotarget.13952","volume":"8","author":"X Wang","year":"2017","unstructured":"Wang\u00a0X, Luo\u00a0Y, Li\u00a0M et\u00a0al (2017) Management of salivary gland carcinomas\u2014a\u00a0review. Oncotarget 8:3946\u20133395","journal-title":"Oncotarget"},{"key":"926_CR29","doi-asserted-by":"publisher","first-page":"5392","DOI":"10.4049\/jimmunol.169.10.5392","volume":"169","author":"CJ Workman","year":"2002","unstructured":"Workman\u00a0CJ, Dugger\u00a0KJ, Vignali\u00a0DAA (2002) Cutting edge: molecular analysis of the negative regulatory function of lymphocyte activation gene\u20113. J\u00a0Immunol 169:5392\u20135395","journal-title":"J Immunol"},{"key":"926_CR30","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1111\/his.13944","volume":"75","author":"B Xu","year":"2019","unstructured":"Xu\u00a0B, Jungbluth\u00a0AA, Frosina\u00a0D et al (2019) The immune microenvironment and expression of PD-L1, PD\u20111, PRAME and MHC I in salivary duct carcinoma. Histopathology 75:672\u2013682","journal-title":"Histopathology"}],"container-title":["HNO"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00106-020-00926-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00106-020-00926-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00106-020-00926-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,13]],"date-time":"2021-09-13T23:14:37Z","timestamp":1631574877000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00106-020-00926-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,14]]},"references-count":30,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["926"],"URL":"https:\/\/doi.org\/10.1007\/s00106-020-00926-w","relation":{},"ISSN":["0017-6192","1433-0458"],"issn-type":[{"value":"0017-6192","type":"print"},{"value":"1433-0458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,14]]},"assertion":[{"value":"14 September 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"M.F.\u00a0Meyer: Advisory Board: MSD und BMS. Doescher J: Advisory Board: MSD. C.\u00a0Arolt, B.\u00a0A.\u00a0Kansy, J.\u00a0Doescher, A.\u00a0Quaas, D.\u00a0Beutner, S.\u00a0Lang und J.\u00a0P.\u00a0Klu\u00dfmann geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}